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ABSTRACT
This report describes the ﬁrst patient in Cyprus to
be infected with a vancomycin-resistant enterococ-
cus, aswell as themicrobiological characteristics of
a cluster of vancomycin-resistant enterococcus
isolates from the intensive care unit where the
index case was hospitalised. All isolates were
identiﬁed as Enterococcus faecalis, belonged to the
same clone, and contained the vanA gene cluster.
Transfer of glycopeptide resistance to a susceptible
strain of E. faecalis could not be detected.
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Vancomycin-resistant enterococci (VRE) were ﬁrst
isolated in Europe in 1986, and then subsequently
in the USA. In the past 10 years, VRE have been
reported to cause nosocomial infections in
Europe, the USA and other geographical regions
[1–3]. However, there have been no previous
reports of infection or colonisation with VRE on
the island of Cyprus in the southeastern-most part
of Europe. This study describes the clinical
features of the ﬁrst patient in Cyprus with
vancomycin-resistant enterococcus infection, as
well as the microbiological characteristics of an
associated cluster of isolates of VRE.
The patient was a 34-year-old Caucasian male
who was admitted to the intensive care unit (ICU)
of the Nicosia General Hospital, Cyprus, follow-
ing a car accident. The patient had multiple
traumas and cranioencephalic injury, with an
epidural haematoma, and underwent a cranioto-
my on the day of admission. Fever developed
post-operatively, and this was treated empiric-
ally, initially with ceftriaxone, and subsequently
with vancomycin and meropenem. One month
following craniotomy, blood cultures grew an
Enterococcus faecalis isolate that was resistant to
vancomycin, but susceptible to ampicillin, and a
Staphylococcus aureus isolate that was resistant to
methicillin. Vancomycin-resistant E. faecalis was
also isolated from the patient’s surgical wound
and from the tip of the central catheter. The
central line was removed, and the patient
received ampicillin (3 g every 4 h) and vancomy-
cin (1 g every 12 h) for 2 weeks. The patient was
discharged in good health after 2 months.
Rectal swabs from nine patients who were
resident in the ICU during the same period were
examined for the presence of VRE by plating on to
brain–heart infusion (BHI) agar containing vanco-
mycin 6 mg ⁄L. Five of the nine rectal swabs
yielded vancomycin-resistant E. faecalis. Isolation
precautions, as recommended by the USA
Hospital Infection Control Practices Advisory
Committee [4], were implemented for all patients
colonised with VRE.
Isolates were identiﬁed as E. faecalis with the
API 20 Strep system (bioMe´rieux, Marcy-l’Etoile,
France), and susceptibilities to commonly used
antimicrobial agents were determined by the broth
microdilutiom method [5]. High-level resistance
to aminoglycosides was conﬁrmed by testing
bacterial growth on BHI agar containing either
gentamicin or streptomycin 2000 mg ⁄L. b-Lacta-
mase production was examined with nitrocephin
disks. Possible transferability of vancomycin
resistance was examined in ﬁlter matings, as
described previously [6], with E. faecalis strain
FA2-2 (resistant to rifampicin and fusidic acid) as
the susceptible recipient strain [7] and incubation
at 37C for 6–8 h and for 24 h on BHI agar
containing rifampicin, fusidic acid and vancomy-
cin. Transfer frequencies were expressed as the
number of transconjugants ⁄ recipient cell present
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at the time of plating on the selective medium.
The relatedness between isolates was examined,
as described previously [8], by pulsed-ﬁeld gel
electrophoresis of genomic DNA digested with
SmaI, using clamped homogeneous electric ﬁelds
(CHEF-DRIII apparatus; Bio-Rad, Hemel
Hempstead, UK). Guidelines published previ-
ously [9] were used to interpret the pulsed-ﬁeld
gel electrophoresis proﬁles. Following lysis of
bacterial cells and extraction of DNA with the
QIAmp DNA Mini kit (Qiagen, Valencia, CA,
USA), the isolates were examined by PCR for the
presence of the vanA, vanB and vanC genes [10].
E. faecalis strain FA2-2 and a vancomycin-resistant
enterococcus clinical isolate from Greece that was
known to carry the vanA gene complex were used
as negative and positive controls, respectively.
All E. faecalis isolates investigated had the
VanA phenotype, producing a 1030-bp PCR
product corresponding to the vanA gene cluster,
and vancomycin and teicoplanin MICs of
> 256 mg ⁄L and >64 mg ⁄L, respectively. All the
isolates also exhibited high-level resistance to
gentamicin and streptomycin. Susceptibilities to
other antibiotics were (mg ⁄L): penicillin 16;
linezolid 0.75; ciproﬂoxacin > 32; tetracycline
> 16; and quinopristin–dalfopristin > 32. None of
the isolates produced b-lactamase. Transfer of
vancomycin resistance to E. faecalis FA2-2 was not
detected (< 10)9 transconjugants ⁄ recipient cell),
even after prolonged mating for 24 h. Five isolates
of VRE from ﬁve different patients yielded iden-
tical SmaI pulsed-ﬁeld gel electrophoresis proﬁles
(Fig. 1), thereby demonstrating the ﬁrst reported
cluster of isolates of VRE in Cyprus.
The origin of VRE in Cyprus, and the factors
associated with the emergence of vancomycin
resistance, are unknown. In Cyprus, there have
been no regulations regarding the use of antibi-
otics in animals, and the addition of antibiotics
(e.g., avoparcin) as growth promoters to animal
feeds may have been a factor in the emergence of
VRE. Another contributory factor may have been
a signiﬁcant increase in the use of vancomycin
because of the increasing incidence of methicillin-
resistant S. aureus infections in most hospitals on
the island. It is also possible that strains of VRE
could have been imported to Cyprus from a
neighbouring country (e.g., Greece).
The epidemiology of VRE is characterised by
geographical variation. In Europe, it has been
suggested that VRE may have emerged in the
community following the use of avoparcin in
animals, whereas VRE may have emerged in the
USA followingwidespread use of oral vancomycin
[3]. Faecal colonisation by VRE is quite frequent in
some areas of Europe, but almost non-existent in
individuals living in the community in the USA
[11,12]. In contrast, the rates of colonisation and
infection with VRE in hospitals are far greater in
the USA than in Europe. Data suggest that the
epidemiology of VRE is now changing rapidly,
with community dissemination of these organisms
in the USA, and an increasing incidence of nosoco-
mial infection with VRE in some European coun-
tries [13,14]. At present, there are insufﬁcient data
regarding colonisation with VRE among healthy
individuals and hospitalised patients in Cyprus.
When the vancomycin-resistant enterococcus
infection in the patient described in this report
Fig. 1. Pulsed-ﬁeld gel electrophoresis of SmaI-digested
genomic DNA from vancomycin-resistant Enterococcus
faecalis isolates. Lanes: 1, lambda ladder DNA standard;
2, blood isolate; 3–6, rectal swab isolates from intensive
care unit patients; 7, E. faecalis strain FA2-2 (negative
control); 8, clinical isolate carrying vanA (positive
control).
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was ﬁrst recognised, ﬁve of nine ICU patients
were already colonised with VRE. The ratio of
VRE-infected patients to VRE-colonised patients
varies from minimal in immunocompetent hosts,
to 85% in severely immunocompromised patients
[15]. The infection-to-colonisation ratio observed
in the present report (one of ﬁve patients, 20%)
probably reﬂects the intermediate severity of the
underlying diseases of the patients studied.
Despite the high mortality rate associated with
bacteraemia caused by VRE [16], the patient in the
present study survived following intravenous
administration of high doses of ampicillin, com-
bined with removal of an intravenous catheter.
Strict adherence to isolation precautions was
successful in preventing further transmission of
VRE, and no other instances of infection or
colonisation were found by follow-up surveil-
lance cultures of ICU patients.
In view of the very efﬁcient transmission of
VRE in a hospital environment, and the difﬁculty
of effective control once colonisation with VRE
has become endemic, surveillance cultures of
high-risk patients upon admission, combined
with contact isolation of VRE-positive patients
and appropriate policies for antibiotic use, may be
required to contain the dissemination of these
problematic organisms.
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